bhq-880
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00741377)
Timeline
Indications
Mechanism of action
- Dickkopf-related protein 1INHIBITOR
DKK1 inhibitor
Can neutralize both human DKK1 and murine DKK1.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109381 ↗
Also known as
- bhq880
- bhq880
- bhq-880
- bhq-880
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01337752 | Phase 2 | Jan 1, 2012 | Novartis |
| NCT01302886 | Phase 2 | May 1, 2011 | Novartis |
| NCT00741377 | Phase 1 | Jan 1, 2009 | Novartis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 2 | 2009 |
1 organizations
Page 1 / 1